OPN-2853 / Opna Bio  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OPN-2853 / Opna Bio
NCT03297424: A Study of PLX2853 in Advanced Malignancies.

Completed
1b
49
US
PLX2853, PLX2853 tablets
Opna-IO LLC
Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma, Advanced Malignancies, Solid Tumor, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
06/21
06/21
NCT03787498: A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Completed
1b
22
US
PLX2853
Opna-IO LLC
Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
06/21
06/21
2019-000916-27: A study investigating the combination of two drugs (PLX2853 and ruxolitinib) in patients with intermediate-2 or high risk myelofibrosis who are not receiving an adequate response with ruxolitinib alone.

Not yet recruiting
1
60
Europe
PLX2853, Jakavi, Tablet, Jakavi
University of Birmingham
Myelofibrosis, Myelofibrosis, Diseases [C] - Cancer [C04]
 
 

Download Options